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Abstract 
T cells detect infected and transformed cells via antigen presentation by major 
histocompatibility complex (MHC) molecules on the cell surface. For T cell stimulation these 
MHC molecules present fragments of proteins that are expressed or taken up by the cell. 
These fragments are generated by distinct proteolytic mechanisms for presentation on MHC 
class I molecules to cytotoxic CD8+ and on MHC class II molecules to helper CD4+ T cells. 
Proteasomes are primarily involved in MHC class I ligand, and lysosomes in MHC class II 
ligand generation. Autophagy delivers cytoplasmic material to lysosomes, and, therefore, 
contributes to cytoplasmic antigen presentation by MHC class II molecules. In addition, it has 
been recently realized that this process also supports extracellular antigen processing for 
MHC class II presentation and cross-presentation on MHC class I molecules. Although the 
exact mechanisms for the regulation of these antigen processing pathways by autophagy are 
still unknown, recent studies, summarized in this review, suggest that they contribute to 
immune responses against infections and to maintain tolerance. Moreover, they are targeted 
by viruses for immune escape, and could maybe be harnessed for immunotherapy.  
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Introduction 
T cells detect infected or transformed cells via antigen presentation by major 
histocompatibility complex (MHC) molecules on the cell surface. Helper CD4+ T cells and 
cytotoxic CD8+ T cells are restricted by MHC class I and II molecules, respectively. These 
molecules display antigens in the form of peptides on the cell surface. These peptides are 
generated via distinct proteolytic processes and loaded in different cellular compartments on 
MHC class I and II molecules. Some antigen processing for peptide presentation by MHC 
molecules is assisted by autophagy. 
 CD8+ T cells, which rapidly expand during immune responses and mediate 
cytotoxicity against infected and tumor cells, recognize octamer or nonamer peptides on 
MHC class I molecules 1. These peptides are thought to originate primarily from protein 
degradation by proteasomes, large multicatalytic proteases in cytosol and nucleus 2. These 
peptides are then imported into the endoplasmic reticulum (ER) via the transporter 
associated with antigen processing (TAP), and can be further trimmed on their N-terminus 
via ER aminopeptidases associated with antigen processing (ERAAPs) 3. Peptides that fulfil 
the binding requirements for the expressed MHC class I molecules, so-called binding motifs, 
are then loaded into the peptide binding groove of these molecules in the MHC class I 
loading complex. Upon binding of high-affinity ligands, MHC class I molecules and their 
peptide cargo are then released from the ER to travel to the cell surface for immune 
surveillance by CD8+ T cells. This model of antigen loading onto MHC class I molecules 
predicts that proteasome substrates are the main source of MHC class I ligands. Originally, it 
was assumed that MHC class I molecules would, therefore, primarily present cytosolic and 
nuclear antigens. However, it was noted that certain cell types, primarily professional antigen 
presenting cells like dendritic cells (DCs) are capable to display extracellular antigens on 
MHC class I molecules by antigen processing via cross-presentation 4-5. During cross-
presentation endocytosed antigen is thought to escape into the cytosol by so far poorly 
defined mechanisms. Whole proteins or preprocessed protein fragments might be delivered 
to the cytosol and at least for some antigens vesicular degradation by insulin regulated 
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aminopeptidase (IRAP) is required for efficient crosspresentation 6. In the cytosol cross-
presented antigens can access the proteasome and follow the MHC class I antigen 
processing and presentation pathway. The stage of endosomal maturation, from which 
cross-presented antigen is exported, is heavily debated, and early endosomes as well as late 
endosomes, including some that might even fuse with the ER, have been implicated 7-10. 
Thus different antigen formulations might be cross-presented from different endosomes, but, 
as we will discuss later, antigen assisted in its exocytosis by macroautophagy might access 
one of these cross-presenting compartments very efficiently. 
 In contrast to MHC class I molecules, MHC class II molecules present longer peptides 
of heterogenic size (≥9 amino acids long) to CD4+ T cells, which orchestrate humoral and 
cellular immune responses by virtue of their cytokine production. MHC class II ligands are 
primarily products of lysosomal proteolysis 11, and are loaded with these in late endosomal 
compartments, called MHC class II loading compartment (MIIC). MHC class II molecules 
reach these late endosomes with the help of a chaperone called invariant chain (Ii), which 
prevents premature peptide binding of MHC class II molecules in ER and Golgi apparatus, as 
well as guides MHC class II molecules via its cytosolic domain to MIICs. In these vesicles Ii is 
degraded by lysosomal proteolysis, and the remnant peptide occupying the peptide binding 
groove, class II-associated invariant chain peptide (CLIP), is expelled with the help of the 
chaperones H2-M or HLA-DM in mouse and man, respectively. These chaperones also 
ensure high affinity peptide ligand binding to MHC class II molecules. Thus, MHC class II 
presented antigens are in their majority proteins that can gain access to the MIIC. In the 
classical paradigm of MHC class II antigen processing, these were thought to be exclusively 
extracellular protein that reach the MIIC after endocytosis. As discussed later, it has now 
been realized that autophagy can permit cytoplasmic antigen to also access this pathway.  
 With respect to autophagic pathways that can be involved in antigen processing for 
MHC presentation, only macroautophagy and chaperone-mediated autophagy have so far 
been investigated, and we want to briefly introduce the processes and molecules that have 
been used by immunologists to elucidate a role for autophagy in antigen presentation to T 
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cells. During macroautophagy more than 30 autophagy-related gene (atg) products are 
involved in the generation and lysosome fusion of cytosolic double-membrane surrounded 
vesicles, called autophagosomes 12. The sites of autophagosome generation are 
characterized by the assembly of type III phosphoinositide-3 (PI3) kinase complexes, 
incorporating Atg6/Beclin-1. Both rough ER and the outer nuclear leaflet have been identified 
as autophagosome formation sites 13-15, but these vesicles might also be generated at other 
places. Two ubiquitin-like systems are involved in autophagosome formation at these sites 
with Atg8 and Atg12 as the ubiquitin-like molecules at their center 16. In one ubiquitin-like 
system Atg12 gets coupled to Atg5 with the assistance of the E1- and E2-like enzymes Atg7 
and Atg10. The Atg12-Atg5 heterodimer then associates with Atg16L1 and coates the outer 
autophagosome membrane. It dissociates from the outer membrane, once the 
autophagosome is completed, and has been shown to direct the conjugation of the other 
ubiquitin-like molecule Atg8. Atg8 and its most studied mammalian homologue LC3 are 
coupled to the lipid phosphatydilethanolamine at the outer and inner autophagosomal 
membrane with the help of the E1- and E2-like enzymes Atg7 and Atg3. While it is recycled 
from the outer membrane upon autophagosome completion, it stays associated with the 
inner membrane and is degraded with the autophagosome cargo in lysosomes. Atg8/LC3 
catalyses hemifusion of membranes and might therefore support the elongation of the 
autophagosome membrane 17. In addition, it is used to recruit autophagic cargo 18-20. In 
addition to its role in autophagosome formation, Atg6/Beclin-1 containing PI3 kinase 
complexes are then once more involved in macroautophagy at the stage of autophagosome 
fusion with the lysosome 21-24. In addition to macroautophagy, chaperone-mediated 
autophagy also imports cytosolic proteins into lysosomes for degradation 25. Its substrates 
carry a KFERQ-like signal sequence, which targets them for direct transport across the 
lysosomal membrane. This transport is assisted by cytosolic and vesicular chaperones of the 
heat-shock protein family and the transmembrane protein LAMP2A. Thus both 
macroautophagy and chaperone-mediated autophagy deliver cytoplasmic constituents to 
lysosomes for degradation. Since T cells monitor the proteolytic waste of cells for signs of 
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infection and transformation, it is maybe not surprising that they also survey substrates of 
autophagy. The evidence for this will be discussed below. 
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Antigen processing for MHC class II presentation via autophagy 
Endogenous pathway  
Different studies have now demonstrated that autophagosomes can deliver cytosolic and 
nuclear proteins to MHC class II loading compartments (Figure 1), and this phenomenon 
occurs in different cell types: in epithelial cells, in B cells, but also in dendritic cells, the most 
professional antigen presenting cells. Morphological analysis of MHC class II compartment 
have revealed that betwheen 30 and 50 % of MHC class II compartment co-stain with the 
autophagosome marker Atg8/LC3 26. In parallel, using different model antigens, for the 
generation of which proteins were coupled to Atg8/LC3, our group demonstrated that 
targeting an antigen to macroautophagy significantly enhances its processing and 
presentation on MHC class II molecules 26 and (Gannage et al., unpublished observation). In 
this section we discuss different examples of intracellular antigens from self, viral and tumor 
origin that have been shown to be processed for MHC class II presentation via 
macroautophagy.  
Evidence that self antigens can be delivered to MHC class II loading compartment via 
macroautophagy came first from the analysis of MHC class II bound epitopes. In human B 
lymphoblastoid cell lines, mass spectrometrical analysis of the MHC class II ligandome 
showed that 20 to 30% of self class II epitopes are derived from cytosolic and nuclear 
proteins. A significant change in the MHC presented amount of these peptides occurred 
upon starvation induced macroautophagy 27. This self-antigen presentation via 
macroautophagy might be involved in autoimmune diseases. Along these lines, the group of 
Ludger Klein has implicated macroautophagy in the generation of central tolerance by MHC 
class II antigen presentation of self antigens on thymic epithelial cells (TECs).  Using a model 
of transplantation of Atg5-/- thymi into wild type or TCR transgenic mice, Klein et al.  
demonstrated that thymic macroautophagy shapes the repertoire of CD4+ T cells 28. 
Macroautophagy in cortical TECs seemed to be required for positive selection of certain T 
cell receptor specificities, while in medullary TECs it was required for negative selection. 
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Without macroautophagy dependent negative selection, immunopathology was observed in 
several tissues including the gut, and the symptoms could be transferred by T cells. Similarly, 
Kasai and colleagues demonstrated by immunofluorescence analysis  the colocalization of 
Atg8/LC3 with MHC class II loading compartment in TECs, both in vitro (in cTEC and mTEC 
cell lines) and in vivo (in thymic cryosection) 29. In addition, Western blot analysis of H2-DM 
vesicles isolated from TECs lines detected the lipidated form of Atg8/LC3 (LC3-II), 
suggesting fusion of autophagosomes with these MHC class II loading compartments. It is 
tempting to speculate that macroautophagy allows intracellular antigens, including peripheral 
tissue derived antigen that are transcribed due to the expression of the transcription factor 
autoimmune regulator element (AIRE), to be presented onto MHC class II molecules for 
central tolerance induction by TECs. However, this self-antigen presentation might also result 
in autoimmunity, and Janice Blum’s group has indeed shown that the autoantigens GAD65 
and SMA can be better presented to CD4+ T cells when chaperone-mediated autophagy is 
enhanced 30. These data suggest that both macroautophagy and chaperone-mediated 
autophagy transport self-proteins for MHC class II presentation to CD4+ T cells during 
tolerance induction and possibly also autoimmune disease. 
Apart from self-antigens, macroautophagy can also deliver pathogen-derived antigens 
to MHC class II loading compartments. This is exemplified by viral antigens in Epstein Barr 
virus (EBV) infected B cells. The pathway has been implicated in the degradation of two 
latent EBV antigens, EBV nuclear antigen 1 (EBNA1) and latent membrane protein 1 
(LMP1). LMP1 which is considered the major oncogene of EBV, induces macroautophagy 31 
and accumulates upon silencing of the two essentiel macroautophagy gene products 
Atg6/Beclin 1 and Atg7. Therefore, LMP1 seems to regulate its own clearance by 
macroautophagy, but further studies will have to be performed to demonstrate if this results 
in CD4+ T cell epitope generation from LMP1. For the second latent EBV antigen that is at 
least partially turned over by macroautophagy, EBNA1, antigen processing for MHC class II 
presentation via macroautophagy has been demonstrated 32-33. Leung et al. identified 2 
epitopes from EBNA1 that are processed via endogeneous pathways for MHC class II 
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presentation by EBV infected B cells. In line with previously published results from our group 
32, one of these epitopes is delivered to MHC class II loading compartments via 
macroautophagy. Interestingly, preventing nuclear import of EBNA1 by mutating its nuclear 
localization sequence, strongly enhanced the presentation of both this and the other CD4+ T 
cell epitopes. Both of them were now delivered to MHC class II loading compartment via 
macroautophagy. Thus, cytosolic relocation of EBNA1 resulted in broadening the range of 
CD4+ T cell epitopes, displayed on MHC class II molecules after macroautophagy. How the 
relocation of an antigen from the nucleus to the cytosol can enhance its endogeneous 
delivery to MHC class II compartment by macroautophagy remains unclear. In contrast to 
this finding, the study by Riedel et al. 34, suggested that for endogenous MHC class II 
presentation of the cytosolic bacterial antigen neomycin phosphotransferase II (NeoR) via 
macroautophagy, the relocation of the antigen to the nucleus does not affect its antigen 
recognition. The differences in these two studies might be related to the nature and 
expression level of the antigen itself, allowing them to form cytosolic malfolded protein pools 
to different degrees. In another viral infection, Herpes simplex virus type 1 (HSV-1) induces 
macroautophagy, but this response is antagonized by the HSV-1 neurovirulence gene 
product, ICP34.5, which interacts with the essential autophagy protein Atg6/Beclin-1. 
Interestingly, a mutant virus unable to bind to the Atg6/Beclin-1 protein induces a significantly 
stronger CD4+ T cell response in infected mice 35. This might imply an essential role of 
macroautophagy mediated MHC class II presentation during HSV-1 infection. Indeed, Akiko 
Iwasaki and colleagues have recently demonstrated that HSV infection of mice, lacking 
macroautophagy in DCs, was compromised in raising virus specific CD4+ T cell responses 36. 
Finally, in macrophages and DCs infected with mycobacterium tuberculosis (Mtb), induction 
of macroautophagy by rapamycin, IFN- or starvation significantly enhanced the processing 
of immunodominant CD4+ T cell epitopes from the mycobacterial antigen Ag85B 37. This 
mechanism is an active process, occurring only in live Mtb infection, and is specifically 
inhibited by RNA silencing of Atg6/Beclin-1. In addition, vaccination of mice with rapamycin 
pretreated Mtb infected DCs significantly improved the efficiency of T cell responses prior to 
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Mtb challenge. This work described for the first time how the manipulation of 
macroautophagy could improve a vaccine strategy. Thus, MHC class II presentation of 
individual viral antigens via macroautophagy, a role for this pathway in vivo and even 
immune evasion by viral inhibition of macroautophagy has been demonstrated.  
A third group of antigens that might fall prey to macroautophagy, are tumor antigens. 
The implications of macroautophagy during tumorigenesis are still unclear. Among others, 
macroautophagy has been shown to promote cell survival of cancer cells, but also in parallel 
to function as a tumor suppressor pathway in some models. Nevertheless, the pathway is 
active in cancer cells and might generate tumor-derived CD4+ T cell epitopes.  As an 
example, the protein encoded by the Mucin gene 1 (MUC1) has been described to be 
processed by macroautophagy after expression in DCs 38. In MUC1 transfected DCs the 
processing of MUC1 for MHC class II presentation was found to be dependent on 
macroautophagy. This was documented by significant inhibition of MUC1 specific CD4+ T cell 
proliferation during coculture with antigen expressing DCs in the presence of PI3 kinase 
inhibitors (3-methyladenine or wortmannin), which compromise autophagosome generation. 
In contrast, MUC1 specific CD8+ T cell responses were unaffected by this pathway. Thus, 
self-, pathogen-derived and tumor-antigens have now been demonstrated to follow 
macroautophagy for MHC class II presentation to CD4+ T cells. This pathway of immune 
surveillance should be harnessed during vaccination and for the development of novel 
immunotherapies. 
 
Exogeneous pathway  
In addition to its role in MHC class II presentation of cytosolic antigens, macroautophagy has 
recently been shown to participate in the processing of exogeneous antigens and their 
delivery to MHC class II compartment (Figure 1). Evidence for this pathway has been 
gathered primarily in macrophages and DCs. Indeed, three recent studies have established a 
role for macroautophagy in the processing of phagocytosed antigens for MHC class II 
presentation by DCs. Particularly, enhanced antigen processing after DC activation by 
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pathogen associated molecular patterns (PAMPs), as recognized by Toll-like receptors 
(TLRs) and NOD-like receptors (NLRs), was supported by macroautophagy. 
The first study by the group of Akiko Iwasaki highlighted the importance of 
macroautophagy in DCs for CD4+ T cell priming in vivo 36. Interestingly, during herpes 
simplex virus (HSV) infection, macroautophagy seems to be important not only for the 
processing of cytosolic endogeneous antigens and their delivery to MHC class II 
compartment, but also for the processing of exogenous phagocytosed antigens. Using 
chimeric mice reconstituted with a hematopoietic system deficient for Atg5, the authors could 
demonstrate a defect in CD4+ T cell responses in vivo upon HSV infection. In addition, in 
these chimeric mice, adoptively transferred ovalbumin (OVA)-specific CD4+ T cells showed 
an impairment of proliferation after infection with OVA-expressing Listeria monocytogenes or 
OVA expressing HSV. A role of macroautophagy for MHC class II antigen processing and 
presentation in vivo in professional antigen presenting cells was further supported by mice 
with a conditional deletion of Atg5 in their DCs. Indeed in these mice HSV infection failed to 
prime CD4+ T cell responses in vivo, and the mice succumbed to a more severe disease 
compared to wild type mice, and developed a higher clinical score upon infection. In the 
same study, the authors ruled out a general defect in macroautophagy deficient DCs, by 
demonstrating that they had no defect in their migration capability, in their phenotypic 
maturation (CD86, CD40 and MHC class II expression), in their cytokines production and 
were not impaired in endocytosis or phagocytosis  compare to wild type DCs. Instead, the 
defect in extracellular antigen presentation on MHC class II molecules was rather due to an 
impairment of processing of phagocytosed antigens that trigger TLR stimulation. Using 
lipopolysaccharide (LPS) coated OVA beads, an impairment of phagosome to lysosome 
fusion was observed in Atg5-/- DCs, resulting in a reduction of the processing of 
phagocytosed antigen for MHC class II presentation. This phenotype was the consequence 
of a defect in the delivery of lysosomal proteases to phagosomes, as well as a delay of 
fusion of phagosomes with lysosomes. The precise mechanism of how the macroautophagy 
machinery is recruited to phagosomes and might enhance fusion with lysosomes remains 
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unclear, but these findings are in line with previous studies, documenting enhanced antigen 
presentation of TLR ligand coated antigen and Atg supported fusion of phagosomes 
containing such antigen with lysosomes 39-40. In one of these studies, the authors described 
that TLR engagement induces “LC3-associated phagocytosis” (LAP). Upon TLR2 stimulation 
a recruitment of Atg8/LC3 to the phagosomal membrane was observed, resulting in an 
enhanced maturation of the phagosome. These studies suggest that macroautophagy 
facilitates endocytosed antigen delivery to lysosomes, and MHC class II presentation of this 
antigen. 
Along the same lines, Alison Simmons and colleagues demonstrated that upon NOD2 
(nucleotide-binding oligomerization domain-containing-2) activation, macroautophagy is 
upregulated and involved in MHC class II processing of phagocytosed antigens 41. This 
study provided for the first time evidence that a defect in macroautophagy mediated MHC 
class II antigen presentation could result in defective CD4+ T cell responses, which might 
then not be able to control the gut commensals in Crohn disease (CD). This defect in 
macroautophagy mediated MHC class II antigen presentation could be caused by mutations 
in both the Atg16L1 and NOD2 gene, which had been identified as major risk factors for the 
occurrence of the disease. The authors demonstrated that a bacterial peptidoglycan 
muramyl dipeptide (MDP) induces macroautophagy upon NOD2 activation in human DCs. 
MHC class II expression on the cell surface of MDP activated DCs was upregulated and this 
up-regulation was dependent on macroautophagy. In parallel a colocalization of Atg8/LC3 
with MHC class II loading compartments was observed. Moreover, DC-mediated priming of 
CD4+ T lymphocytes after Salmonella enterica infection was dependent on NOD2 and 
Atg16L1, because CD4+ T cell proliferation was compromised by siRNA mediated silencing 
of these two genes. The second part of this study analyzed the function of DCs from CD 
patients, carrying either the NOD (3020insC) or the Atg16L1 (T300A) mutation, which are 
associated with the familial form of the disease. In both cases, the cells demonstrated a 
defect in macroautophagy up-regulation upon MDP stimulation or Salmonella enterica 
infection.  As a consequence MHC class II upregulation and CD4+ T cell proliferation were 
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compromised. Confirming these findings, the group of Dana Philpott could demonstrate that 
NOD1 and 2 stimulation up-regulated macroautophagy and led to autophagosome 
recruitment to the plasma membrane 42. This regulation was independent of the classical 
pathway of NLR activation, involving usually the RIP2 adaptor and NF-B transcription 
factor. These data suggested that also NLR-ligand stimulated MHC class II up-regulation 
and antigen presentation requires macroautophagy. 
Finally, a third recent study describes a new mechanism of immune escape of HIV-1 
virus in DCs 43. In this work, HIV-1 was shown to inhibit macroautophagy initiation by 
activating the mTor pathway. This inhibition resulted in an impairment of TLR4 and TLR8 
activation by viral replication intermediates and of antigen presentation to CD4+ T cells. 
Indeed in an in vitro essay of DC capture of inactivated HIV virus, macroautophagy was 
shown to be important for MHC class II antigen processing of a HIV gag-derived CD4+ T cell 
epitope. TNF- secretion of a HIV gag specific CD4+ T cell clone, was significantly reduced 
upon stimulation with macroautophagy deficient DCs, pulsed with inactivated HIV virus. In 
parallel, CD8+ T cell activation was not compromised by macroautophagy inhibition. This 
study suggests that efficient HIV antigen processing for MHC class II presentation by DCs 
requires macroautophagy. 
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Macroautophagy in antigen processing for MHC class I presentation  
In contrast to a quite robust role for macroautophagy in MHC class II antigen presentation, 
much less is known about how this pathway influences antigen processing for MHC class I 
presentation. Indeed in several studies MHC class I restricted antigen recognition was 
actually used as a control and no effect of macroautophagy inhibition on CD8+ T cell 
recognition was observed 26,36,43. However, under certain circumstances macroautophagy 
might enhance antigen presentation on MHC class I molecules to CD8+ T cells, and we will 
summarize the so far sparse evidence for this here. 
The only study so far that argues for a role of macroautophagy in endogenous 
antigen processing for MHC class I presentation by the group of Michel Desjardins 
suggested that late during HSV infection macroautophagy supports MHC class I presentation 
of viral antigens 15. This in vitro finding was restricted to an immunodominant CD8+ T cell 
epitope of the glycoprotein B of the virus, and to its processing during the late stage of the 
infection. Interestingly early after infection (6-8h), the presentation of this epitope followed the 
classical MHC class I pathway, but later on (8-12h), macroautophagy inhibition compromised 
presentation to CD8+ T cells, even so processing of this antigen was still dependent on 
components of the classical MHC class I antigen processing pathway like the proteasome 
and TAP. In infected macrophages, the authors demonstrated that silencing the essential 
autophagy gene atg5 resulted in a decrease of HSV gB specific CD8+ T cell recognition. 
Electron microscopy analysis revealed that the formation of autophagosomes after HSV-1 
infection involved the outer nuclear membrane. However, it was not clarified by which 
mechanism autophagosome cargo can escape to the cytosol to be further processed by 
proteasomes. Irrespective of the mechanism, this study suggests that macroautophagy might 
intersect with the cross-presentation pathway of MHC class I antigen processing. 
A similar intersection with endosomes capable of cross-presentation was proposed 
for macroautophagy substrates of antigen donor cells (Figure 1). The first report showing a 
direct involvement of macroautophagy in crosspresentation was by Li and colleagues 44. In 
this study 293T cells expressing the model antigen OVA in vitro, or melanoma cells 
expressing the gp100 melanoma antigen in vivo, were used as donor cells to access 
crosspresentation. In both cases siRNA mediated silencing of macroautophagy in antigen 
donor cells resulted in a significant reduction of CD8+ T cell activation after cross-
presentation by DCs. Interestingly, purified autophagosomes from antigen donor cells were 
also efficiently cross-presented to CD8+ T cells, probably acting like exosomes. Therefore, 
antigen wrapped in macroautophagic membranes might be more efficiently taken up by 
antigen presenting cells and cross-presented on MHC class I molecules.  
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In a second report along these lines by the group of Matthew Albert 45, evidence was 
provided that efficient cross-presentation of viral antigens required  macroautophagy in 
antigen donor cells. In this study two cellular sources were used to provide antigen for cross-
presentation experiments, wild type mouse embryonic fibroblasts (MEFs) and  Bax/Bak-/-
MEFs. While wild-type MEFs can undergo caspase-dependent apoptosis, Bax/Bak-/-MEFs 
are unable to perform this type of cell death, but up-regulate macroautophagy under the 
applied treatment conditions. Both cell types were infected with influenza A virus, than 
treated with proapoptotic agents and adoptively transferred in vivo for priming experiment. 
Mice immunized with Bax/Bak-/- MEFs showed a significantly higher CD8+ T cell response 
specific to both HA518-526 and NP 366-374 immunodominant CD8+ T cell epitopes, compared to 
mice immunized with wild-type MEFS. These findings again suggest that macroautophagy 
might package antigen efficiently for cross-presentation by DCs. How macroautophagic 
substrates, however, leave antigen donor cells for cross-presentation, remains to be 
determined. 
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Viral evasion from macroautophagy 
The important role of macroautophagy during immune responses is further underscored by 
its regulation during viral infections. Three in vivo systems have linked macroautophagy to 
immune control of viral infections. These included with Herpes simplex virus (HSV) one DNA 
and with Sindbis virus and vesicular stomatitis virus (VSV) two RNA virus. Neurovirulence of 
both HSV and Sindbis virus was attenuated when macroautophagy was elevated either by 
mutation of the macroautophagy inhibiting ICP34.5 HSV gene product 46, or by 
overexpression of Atg6/Beclin-1, driving macroautophagy, in Sindbis virus infected mice 47. 
Furthermore, Sindbis virus infection of the CNS is augmented by macroautophagy inhibition 
via either recombinant viruses encoding a dominant negative Atg5 protein, recombinant 
viruses deleting floxed Atg5 upon infection via cre-recombinase expression or wild-type virus 
infection of mice with conditional Atg5 deletion in neurons 48. In addition, VSV infection 
induced macroautophagy in Drosophila flies, and restricted VSV infection in this model 
organism 49. These studies did not implicate antigen processing for MHC presentation via 
macroautophagy in the protection from virus infection. However, during HSV infection, 
macroautophagy in myeloid DCs was found to be required for efficient priming of protective 
CD4+ T cell responses 36. These studies implicate that macroautophagy restricts viral 
replication in vivo. 
Another indication that macroautophagy significantly limits viral replication is that 
successful viral pathogens have developed immune escape mechanisms to target this 
pathway. In this respect, two checkpoints of macroautophagy are inhibited by viruses. These 
are autophagosome formation and autophagosome fusion with lysosomes. Interestingly, 
DNA viruses seem to primarily compromise autophagosome formation, while RNA viruses 
block autophagic cargo degradation in lysosomes. With respect to the inhibition of 
autophagosome formation, herpesviruses have proven a rich source of macroautophagy 
inhibiting proteins. Within the -herpesviruses, HSV encodes the late infected cell protein 
(ICP) 34.5, which blocks autophagosome formation 50-51. ICP34.5 inhibits autophagosome 
generation by binding to Atg6/Beclin-1 46. Interestingly, HSV with a mutant ICP34.5 protein, 
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lacking the Atg6/Beclin-1 interacting domain, shows increased neurovirulence after CNS 
injection in mice 46. Within the -herpesviruses, human cytomegalovirus (HCMV) also inhibits 
macroautophagy 52. However, the molecular mechanism of this regulation is unknown so far. 
Finally, the group of -herpesviruses contains several members that compromise 
autophagosome formation, namely Kaposi sarcoma associated herpesvirus (KSHV) and 
murine -herpesvirus (MHV-68). KSHV encodes a B-cell lymphoma 2 protein (Bcl-2) 
homologue, encoded by ORF-16 of the virus, which also interacts with Atg6/Beclin-1 and 
inhibits autophagsome formation 53. In addition, the same virus compromises 
autophagosome formation also via its viral FLICE inhibitory protein (v-FLIP) protein, encoded 
by ORF71/K13 54. KSHV v-FLIP impairs Atg3, the E2-like enzyme of Atg8/LC3 lipidation. This 
mechanism prevents Atg8/LC3 dependent autophagosome formation. Therefore, KSHV 
expresses with v-FLIP a macroautophagy inhibitor during latent, and with v-Bcl-2 one during 
lytic infection.  The closest rodent virus to KSHV, MHV-68 also expresses a Bcl-2 
homologue, M11, which interacts with Atg6/Beclin-1 to inhibit autophagosome formation 55. 
Deletion of the macroautophagy blocking, but not the apoptosis compromising domain, 
impairs the establishment of chronic infection by this virus 56. Collectively, these data suggest 
that herpesviruses inhibit autophagosome formation in order to inhibit restriction of viral 
infection and viral antigen presentation. 
In addition to autophagosome generation as a first checkpoint of macroautophagy, 
degradation of these vesicles via fusion with lysosomes is targeted by RNA viruses. Already 
early electron microscopy studies of poliovirus infected cells reported the accumulation of 
double-membrane engulfed vesicles 57. This stabilization of autophagosomes could be 
induced by the viral proteins 2BC and 3A 58, even so the molecular mechanism underlying 
this presumed block in autophagosome degradation remains unclear. Formation of these 
poliovirus stabilized vesicles is dependent on some Atg proteins, because siRNA mediated 
silencing of Atg8/LC3 and Atg12 inhibits their generation, and they seem to represent, 
therefore, a subtype of autophagosomes 58. The stabilized membranes support viral 
replication and are thought to function as a scaffold for viral replication. In addition, inhibition 
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of autophagosome degradation might enhance virus particle exocytosis 58. Furthermore, the 
stabilization of autophagosome membranes for viral replication has been proposed for other 
RNA viruses, like the flaviviruses hepatitic C virus (HCV) and dengue virus 59-63. Moreover, 
even RNA viruses that do not use autophagosomal membranes for their replication, seem to 
benefit from inhibition of autophagosome degradation for their release of infectious viruses 
from infected cells 64. Along these lines the human immunodeficiency virus (HIV) was found 
to block autophagosome maturation. Particularly its Nef protein interacts with Atg6/Beclin-1 
blocking degradation of macroautophagic cargo, including HIV particles. These, therefore, 
are exocytosed at increased rates. This benefit for HIV in blocking autophagosome 
degradation was only observed in macrophages, but not T cells. Similarly, a slight benefit of 
macroautophagy regulation for the replication of the segmented RNA virus influenza virus 
was observed only in canine kidney epithelial cells, but not in human lung epithelia or mouse 
embryonic fibroblasts 65-66. Irrespective of a benefit for viral replication, influenza infection 
leads to autophagosome accumulation in a broad range of cell types 66. The virus achieves 
this by blocking autophagosome fusion with lysosomes via its matrix protein 2 (MP2). This 
macroautophagy block enhances apoptotic cell death of infected cells and might regulate 
immunogenic viral protein release. Taken together these studies suggest that viruses 
highjack macroautophagy to prevent their degradation and viral antigen presentation, or even 
use autophagic membranes for their own replication and exit from infected cells. Depending 
on the need of the virus they block autophagosome generation or degradation with DNA 
viruses targeting preferentially the first, and RNA viruses the second check-point of 
macroautophagy, respectively. 
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Conclusions 
Macroautophagy supports adaptive immune responses by facilitating antigen processing for 
MHC presentation to T cells. Since autophagosomes direct cytoplasmic content for 
lysosomal degradation and MHC class II molecules present lysosomal products to CD4+ T 
cells, most studies suggest a role for macroautophagy in antigen presentation to these helper 
T cells. However, some studies also describe that macroautophagy might even assist MHC 
class I antigen presentation to CD8+ T cells. While intracellular antigen presentation by MHC 
class II molecules seems to benefit from macroautophagic substrate delivery to MHC class II 
loading compartments, the mechanisms by which extracellular antigen delivery to these 
MIICs is supported by macroautophagy, by which autophagosome content can again escape 
to the cytosol for classical MHC class I antigen presentation, and by which antigen can be 
efficiently packaged by macroautophagy for cross-presentation remain unclear. The 
evidence that viruses, however, target this pathway for their immune escape suggests that it 
might be important for immune control. Thus, macroautophagy should be harnessed to 
enhance immunotherapies and assist antigen processing during vaccinations. 
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Figure legend 
Figure 1: Macroautophagy assists in antigen processing for MHC class I and II 
presentation. Cytosolic antigen can be directly transported to MHC class II loading 
compartments (MIIC) via autophagosomes (lower left). In addition, it might escape lysosomal 
degradation and get exocytosed from multivescular bodies (MVB) for uptake by bystander 
cells (right and upper left). The endocytosed antigen might get loaded onto MHC class II 
molecules or escape to the cytosol for proteasomal degradation and presentation on MHC 
class I molecules.   
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